(Q30868034)

27 June 2017

1 reference

title

Olanzapine for schizophrenia. (English)

1 reference

27 June 2017

Olanzapine for schizophrenia (English)

0 references

1 reference

L Duggan

1

1 reference

27 June 2017

M Fenton

2

1 reference

27 June 2017

R M Dardennes

3

1 reference

27 June 2017

A El-Dosoky

4

1 reference

27 June 2017

S Indran

5

1 reference

27 June 2017

language of work or name

English

0 references

publication date

1 January 2000

1 reference

Cochrane Database of Systematic Reviews

27 June 2017

2003

0 references

published in

1 reference

27 June 2017

CD001359

1 reference

27 June 2017

2

1 reference

The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations

27 June 2017

1

0 references

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359

Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359

Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359

Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359

Olanzapine versus haloperidol treatment in first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359

Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359

The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359

Olanzapine: a novel atypical neuroleptic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359

High-dose olanzapine for treatment-refractory schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359

Using the proportional odds model to assess the relationship between a multi-item and a global item efficacy scale in a psychiatric clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359

Negative symptoms in schizophrenia. Definition and reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359

A rating scale for drug-induced akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359

Bias in treatment assignment in controlled clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359

ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359

Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359

The well-being of chronic mental patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359

Serotonergic basis of antipsychotic drug effects in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359

Dopamine receptors and the dopamine hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359

Content and quality of 2000 controlled trials in schizophrenia over 50 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359

Cost Analysis of the Treatment of Schizophrenia in the UK

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359

10.1002/14651858.CD001359

21 January 2018

Identifiers

DOI

1 reference

release_vtmupycpbrb4plm4snrmcan5iu

27 June 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vtmupycpbrb4plm4snrmcan5iu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference